1. US Prostate Cancer Drug Market Overview

2. Approved Prostate Cancer Drugs Insight by Class

  2.1 Chemotherapeutic Drugs

  2.2 Hormonal Therapy

  2.3 Immunotherapy

    2.3.1 Cancer Vaccines

    2.3.2 Immune Checkpoint Inhibitors

  2.4 PARP Inhibitors

3. Novel Emerging Therapies in Prostate Cancer

  3.1 Bi-Specific T-Cell Engagers (BiTE)

  3.2 Small Molecule Prostate Cancer Drugs

  3.3 Radioligand Therapy

  3.4 Antibody Drug Conjugates

4. US Prostate Cancer Drugs: Generic and Biosimilar Landscape

  4.1 Current Scenario and Price Differential

  4.2 Reimbursement Scenario

5. Anti-Androgen Drugs for Prostate Cancer – US Market Availability, Dosage, Patent and Price Insight

  5.1 Apalutamide (Erleada)

  5.2 Xtandi (Enzalutamide)

  5.3 Darolutamide (Nubeqa)

  5.4 Abiraterone (Zytiga)

  5.5 Bicalutamide (Casodex)

  5.6 Nilutamide (Nilandron)

  5.7 Flutamide

6. PARP Inhibitors for Prostate Cancer – US Market Availability, Dosage, Patent and Price Insight

  6.1 Rucaparib (Rubraca)

  6.2 Olaparib (Lynparza)

7. Radioactive Pharmaceutical Agents for Prostate Cancer – US Market Availability, Dosage and Price Insight

  7.1 Radium 223 Dichloride (Xofigo)

  7.2 Fluciclovine 18F (Axumin)

8. Mitotic Inhibitors for Prostate Cancer - US Market Availability, Dosage, Price and Patent Insight

  8.1 Cabazitaxel (Jevtana)

  8.2 Docetaxel (Taxotere)

9. Immunotherapeutics for Prostate Cancer – US Market Availability, Dosage and Price Insight

  9.1 Provenge (Sipuleucel – T)

  9.2 Capromab Pendetide (ProstaScint)

10. Gonadotropin Releasing Hormones Drugs for Prostate Cancer - US Market Availability, Dosage and Price Insight

  10.1 Triptorelin (Trelstar)

  10.2 Leuprolide

  10.3 Goserelin (Zoladex)

  10.4 Histrelin Acetate Subcutaneous Implant (Supprelin LA/Vantas)

  10.5 Degarelix (Firmagon/Gonax)

11. Estrogens for Prostate Cancer - US Market Availability, Dosage and Price Insight

  11.1 Estradiol

  11.2 Conjugated Estrogen

12. Other Prostate Cancer Targeting Therapeutics - US Market Availability, Dosage and Price Insight

  12.1 Estramustine (Emcyt)

  12.2 Mitoxantrone (Novantrone)

  12.3 Cyclophosphamide

  12.4 Capecitabine (Xeloda)

  12.5 Zoledronic Acid (Zometa/Reclast)

13. US - Prostate Cancer Drug Clinical Trials Overview

  13.1 By Biomarket

  13.2 By Drug Class

  13.3 By Formulation

  13.4 By Organization

  13.5 By Patient Segment

  13.6 By Phase

14. US - Prostate Cancer Drugs Clinical Pipeline By Company, Indication and Phase

  14.1 Unknown

  14.2 Research

  14.3 Preclinical

  14.4 Clinical

  14.5 Phase-0

  14.6 Phase-I

  14.7 Phase-I/II

  14.8 Phase-II

  14.9 Phase-III

  14.10 Preregistration

  14.11 Registered

15. US - Marketed Prostate Cancer Drugs Clinical Insight

16. US Prostate Cancer Market Dynamics

  16.1 Market Drivers

  16.2 Market Challenges

17. US Prostate Cancer Market Future Prospects

18. Compititive Landscape

  18.1 AbbVie

  18.2 Accord Healthcare

  18.3 Allergan

  18.4 Amgen

  18.5 Astellas Pharma

  18.6 AstraZeneca plc

  18.7 Bayer

  18.8 Bristol Mayer Squibb

  18.9 Clovis Oncology

  18.10 Dendreon

  18.11 Genentech

  18.12 Jassen Pharmaceuticals

  18.13 Merck

  18.14 Mylan

  18.15 Novartis AG

  18.16 Pfizer

  18.17 Roche

  18.18 Sanofi

  18.19 Sun Pharma

  18.20 Teva Pharmaceuticals

Figure 1-1: US - Estimated Cases and Deaths from Prostate Cancer, 2020 and2040

Figure 1-2: US - Prostate Cancer Drug Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-1: Hormonal Therpay Targets in Prostate Cancer

Figure 2-2: Provenge – Mechanism of Action

Figure 2-3: Provenge in Clinical Trials

Figure 2-4: Keytruda – Mode of Action

Figure 2-5: Immune Checkpoint Inhibitors in Clinical Trial

Figure 2-6: PARP Inhibitors- Mode of Action

Figure 4-1: Prostate Cancer – Cost of Treatment (US$)

Figure 4-2: Taxotere and Docetaxel – Cost of Intravenous Solution Per Unit (US$)

Figure 4-3: Zytiga and Abiraterone – Cost of Oral Tablet per unit (US$)

Figure 4-4: Lynpraza – Total Cost of Treatment and Reimbursement Cost (US$)

Figure 4-5: Lynpraza - In Pocket Cost and Out Pocket Cost (%)

Figure 5-1: Erleada – Aragon related Patent Issue and expiration Year

Figure 5-2: Erleada – University of California related Patent Issue and expiration Year

Figure 5-3: Erleada – Price for 120 Tablet Supply and Price per unit of Oral Tablet (US$), January’2021

Figure 5-4: Erleada – Recommended and Reduced Dose for Prostate Cancer Treatment (mg per day), January’2021

Figure 5-5: Xtandi – FDA Approval Year by Indication

Figure 5-6: Xtandi – Patent Issue and Expiration Year

Figure 5-7: Xtandi – Price for 120 Tablet Supply and Price per unit of Oral Tablet (US$), January’2021

Figure 5-8: Xtandi – Recommended and Reduced Dose for Prostate Cancer Treatment (mg per day), January’2021

Figure 5-9: Xtandi – Cost of Single Capsule and Daily Treatment Cost (US$), January’2021

Figure 5-10: Nubeqa – Aragon Related Patent Issue and Expiration Year

Figure 5-11: Nubeqa – Price for 120 Tablet Supply and Price per unit of Oral Tablet (US$), January’2021

Figure 5-12: Nubeqa – Price of Single Tablet and Daily Treatment Cost (US$), January’2021

Figure 5-13: Zytiga – FDA Approval by Indication

Figure 5-14: Zytiga – FDA approval and First generic Approval Year

Figure 5-15: Zytiga – Price for Supply of 120 tablets and Price Per Unit Tablet of 250mg (US$), January’2021

Figure 5-16: Zytiga – Price for Supply of 60 tablets and Price Per Unit Tablet of 500mg (US$), January’2021

Figure 5-17: Generic Abiraterone – Price for Supply of 30 Tablets and 120 tablets and Price Per Unit Tablet of 250mg (US$), January’2021

Figure 5-18: Abiraterone – Daily Treatment Cost Branded v/s Generic (US$), January’2021

Figure 5-19: Casodex – FDA Approval and Patent Expiration Year

Figure 5-20: Casodax – Price for 30 Tablets Supply and Price Per Unit Tablet (US$), January’2021

Figure 5-21: Generic Bicalutamide – Price for 30 Tablets Supply and Price Per Unit Tablet (US$), January’2021

Figure 5-22: Nilandrone – FDA Approval and First Generic Approval Year

Figure 5-23: Eloxatin – FDA Approval Year by Strength of Tablet

Figure 5-24: Nilandrone – Price for 30 Tablet Supply and Price Per Unit Tablet of 150mg (US$), January’2021

Figure 5-25: Nilandrone – Recommended Dose for Prostate Cancer Treatment (mg/day), January’2021

Figure 5-26: Flutamide – Price for 180 Capsule Supply and Price per Unit Capsule of 125mg (US$), January’2021

Figure 5-27: Flutamide – Daily and Monthly Treatment Cost of Prostate Cancer (US$), January’2021

Figure 6-1: Rubraca – FDA Approval Year by Indication

Figure 6-2: Rubraca – FDA Approval Year by Strength

Figure 6-3: Rubraca - Number of Patents by Assignee

Figure 6-4: Rubraca - Patents Expiration Year by Assignee

Figure 6-5: Rubraca – Price for a Supply of 60 Tablets and Price Per Unit Tablet (US$), January’2021

Figure 6-6: Rubraca – Recommended Initial and Reduced Dose (mg/twice daily)

Figure 6-7: US - Rubraca Global Sales Value (US$ Million), 2018 and 2019

Figure 6-8: US - Rubraca Quarterly Sales Value (US$ Million), 2018 and 2019

Figure 6-9: US - Rubraca Quarterly Sales Value (US$ Million), Q1-Q3, 2020

Figure 6-10: Lynparza – FDA Approval Year by Indication

Figure 6-11: Lynparza - Number of Patent Issued by Assignee Name

Figure 6-12: Lynparza – Patent Expiration Year by Assignee

Figure 6-13: Lynparza – Price for 60 and 120 Tablet Supply and Price Per Unit Tablet (US$), Janauary’2021

Figure 6-14: Lynparza – Recommended Dose and Dose after Reduction (mg/day)

Figure 6-15: US - Lynparza Annual Sales Value (US$ Million), 2017 - 2019

Figure 6-16: Lynparza - Annual Sales Value by Region (US$ Million), 2019

Figure 6-17: Lynparza – Annual Sales Value by Region (%), 2019

Figure 6-18: US - Lynparza Quarterly Sales Value (US$ Million), 2019

Figure 6-19: US - Lynparza Quarterly Sales Value (US$ Million), Q1-Q3, 2020

Figure 7-1: Xofigo – Patent Issue and Expiration Year

Figure 7-2: Xofigo – Duration of Single Treatment Cycle and Full Treatment (Weeks)

Figure 7-3: Xofigo – Cost of Single Treatment Cycle and Full Treatment (Weeks)

Figure 7-4: Axumin – Number of Patents by Assignee

Figure 7-5: Axumin – Patent Expiration Year by Assignee

Figure 8-1: Jevtana – Patent Issue and Expiration Year

Figure 8-2: Jevtana – Price for 1.5ml Supply and Price per unit of Intravenous Solution (US$), January’2021

Figure 8-3: Jevtana – Recommended and Incremented Dose of Jevtana for Prostate Cancer (mg/m2/3 weeks)

Figure 8-4: Taxotere – FDA Approval year by Strength

Figure 8-5: Taxotere – First Generic Approval year by Strength

Figure 8-6: Docetaxel – FDA Approval year by Companies

Figure 8-7: Taxotere – Price for 4ml Supply and Price per ml of 20mg/ml Intravenous Solution (US$, January’2021

Figure 8-8: Docetaxel – Average Price for 2ml, 8ml and 16ml Supply 10mg/ml Intravenous Solution (US$, January’2021

Figure 8-9: Docetaxel – Average Price for 1ml, 4ml, 8ml and 10ml Supply 20mg/ml Intravenous Solution (US$, January’2021

Figure 8-10: Docetaxel – Minimum and Maximum Recommended Dose (mg/m2/3 weeks)

Figure 9-1: Provenge – Price for 250 ml Supply and Price per ml of Intravenous Suspension (US$), January’2021

Figure 9-2: Provenge – Cost of Single Treatment Cycle and Cost of Full Treatment (US$), January’2021

Figure 10-1: Trelstar – FDA Approval Year by Dose Strength of Injection

Figure 10-2: Trelstar – Patent Issue and Expiration Year

Figure 10-3: Trelstar – Price for Various Supplies of Intravenous Powder (US$), January’2021

Figure 10-4: Trelstar – Recommended dose by Duration of Treatment Cycle (mg)

Figure 10-5: Leuprolide – FDA approval Year by Brand Name

Figure 10-6: Lupron Depot – Patent Issue and Expiration Year

Figure 10-7: Eligard – Cost of Various Supplies of Subcutaneous Powder for Injection (US$), January’2021

Figure 10-8: Lupron – Cost of Various Supplies of Intramuscular Kit (US$), January’2021

Figure 10-9: Lupron – Cost of Various Supplies of Intramuscular Powder for Injection (US$), January’2021

Figure 10-10: Lutrate – Cost of Various Supplies of Intramuscular Powder for Injection (US$/GBP), January’2021

Figure 10-11: Generic Leuprolide – Average Single Day, Monthly and Annual Treatment Cost of Prostate Cancer (US$), January’2021

Figure 10-12: Leuprolide – Average Annual Treatment Cost Comparison of Branded v/s Generic (US$), January’2021

Figure 10-13: Zoladex – FDA Approval Year by Strength of Implant

Figure 10-14: Zoladex – Patent Issue and Expiration Year

Figure 10-15: Zoladex – Price for Single 3.6mg and 10.8mg Implant (US$), January’2021

Figure 10-16: Zoladex – Recommended dose by Duration of Treatment Cycle (mg)

Figure 10-17: Histrelin – FDA approval Year by Brand Name

Figure 10-18: Supprelin LA – FDA Approval Year by Brand Name

Figure 10-19: Histrelin – Price for Single 50mg Implant by Brand Name (US$), January’2021

Figure 10-20: Degarelix – FDA and PMDA Approval Year

Figure 10-21: Firmagon – Patent Issue and Expiration Year

Figure 10-22: Firmagon – Price for Single 80mg and 120mg Powder for Injection (US$), January’2021

Figure 10-23: Degarelix – Recommended Initial Dose and Maintenance Dose (mg/4weeks)

Figure 11-1: Estrace – Price for 100 Tablets Supply and Price Per Unit Tablet of 0.5mg and 1mg Dose (US$), January’2021

Figure 11-2: Estrace – Price for 100 Tablets Supply and Price Per Unit Tablet of 2mg Dose (US$), January’2021

Figure 11-3: Delestrogen – Price for 5ml Supply and Price per ml of 10mg/ml Intramuscular Solution (US$), January’2021

Figure 11-4: Delestrogen – Price for 5ml Supply and Price per ml of 20mg/ml Intramuscular Solution (US$), January’2021

Figure 11-5: Delestrogen – Price for 5ml Supply and Price per ml of 40mg/ml Intramuscular Solution (US$), January’2021

Figure 11-6: Estradiol Tablet – Price for 100 Tablets Supply and 30 Tablets of 0.5mg Dose (US$), January’2021

Figure 11-7: Estradiol Tablet – Price for 100 Tablets Supply and 30 Tablets of 1mg Dose (US$), January’2021

Figure 11-8: Estradiol Tablet – Price for 100 Tablets Supply and 30 Tablets of 0.5mg Dose (US$), January’2021

Figure 11-9: Estradiol Valerate – Price for 5ml Supply and Price per ml of 20mg/ml Intramuscular Solution (US$), January’2021

Figure 11-10: Estradiol Valerate– Price for 5ml Supply and Price per ml of 40mg/ml Intramuscular Solution (US$), January’2021

Figure 11-11: Estradiol – Minimum and Maximum Oral Dose (mg/day), January’2021

Figure 11-12: Premarin – Price for 100 Tablets Supply and Price Per Unit Tablet of Various Dose Regimens (US$), January’2021

Figure 11-13: Premarin – Price for 1000 Tablets Supply and Price Per Unit Tablet of Various Dose Regimens (US$), January’2021

Figure 11-14: Premarin – Minimum and Maximum Oral Dose (mg/day), January’2021

Figure 12-1: Emcyt – Price for 100 Capsules Supply and Price per unit Capsule of 140mg Dose (US$), January’2021

Figure 12-2: Emcyt – Minimum and Maximum Daily Dose (mg/Kg/day)

Figure 12-3: Mitoxantrone – Price for 10 ml Supply and Price per unit ml of 2mg/ml Intravenous Solution (US$), January’2021

Figure 12-4: Mitoxantrone – Price for 12.5 ml Supply and Price per unit ml of 2mg/ml Intravenous Solution (US$), January’2021

Figure 12-5: Mitoxantrone – Price for 15 ml Supply and Price per unit ml of 2mg/ml Intravenous Solution (US$), January’2021

Figure 12-6: Mitoxantrone – Minimum and Maximum Dose (mg/m2)

Figure 12-7: Cyclophosphamide – Price for various Supplies of intravenous Powder for Injection (US$), January’2021

Figure 12-8: Cyclophosphamide – Price for various Supplies of 200mg/ml intravenous Solution for Injection (US$), January’2021

Figure 12-9: Cyclophosphamide – Price for 100 Capsule Supply of 25mg and 50mg Dose (US$), January’2021

Figure 12-10: Cyclophosphamide – Minimum and Maximum Dose as Single Agent (mg/Kg), January’2021

Figure 12-11: Xeloda – FDA Approval Year and First Generic Approval Year

Figure 12-12: Capecitabine – Price for 60 Tablet Supply and Price per unit of 150mg Branded and Generic tablet (US$), January’2021

Figure 12-13: Xeloda – Price for 120 Tablet Supply and Price per unit of 500mg tablet (US$), January’2021

Figure 12-14: Capecitabine – Price for 120 Tablet Supply and Price per unit of 500mg tablet (US$), January’2021

Figure 12-15: Capecitabine – Duration of Single Treatment Cycle and Full Treatment (Weeks)

Figure 12-16: Zometa – FDA Approval and First Generic Approval Year

Figure 12-17: Reclast – FDA Approval and First Generic Approval Year

Figure 12-18: Zometa – Price for 5ml Supply and Price per ml of Intravenous Solution (US$), January’2021

Figure 12-19: Reclast – Price for 10ml Supply and Price per ml of Intravenous Solution (US$), January’2021

Figure 12-20: Generic Zoledronic Acid – Price for 5ml and 200ml Supply of 4mg/ml Intravenous Solution (US$), January’2021

Figure 12-21: Generic Zoledronic Acid – Price for 100ml and Price per ml of 4mg/100ml Intravenous Solution (US$), January’2021

Figure 12-22: Generic Zoledronic Acid – Price for 100ml and Price per ml of 5mg/100ml Intravenous Solution (US$), January’2021

Figure 13-1: US - Number of Prostate Cancer Drugs in Clinical Trials by Biomarker,  2021 till 2026

Figure 13-2: US - Number of Protate Cancer Drugs in Clinical Trials by Drug Class,  2021 till 2026

Figure 13-3: US - Number of Prostate Cancer Drugs in Clinical Trials by Formulation,  2021 till 2026

Figure 13-4: US - Number of Prostate Cancer Drugs in Clinical Trials by Organization,  2021 till 2026

Figure 13-5: US - Number of Prostate Cancer Drugs in Clinical Trials by Patient Segment,  2021 till 2026

Figure 13-6: US - Number of Prostate Cancer Drugs in Clinical Trials by Phase,  2021 till 2026